tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsTools for Trading PlatformsData for Hedge FundsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

VXRT Stock Latest News

Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus
Press ReleasesVaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus
4d ago
VXRT
Vaxart to host KOL webcast on health, economic impact for norovirus
The FlyVaxart to host KOL webcast on health, economic impact for norovirus
4d ago
VXRT
Vaxart Provides Business Update and Full Year 2022 Financial Results
Press ReleasesVaxart Provides Business Update and Full Year 2022 Financial Results
6d ago
VXRT
Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15
Press ReleasesVaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15
13d ago
VXRT
Vaxart options imply 40.1% move in share price post-earnings
The FlyVaxart options imply 40.1% move in share price post-earnings
14d ago
VXRT
Vaxart options imply 39.1% move in share price post-earnings
The FlyVaxart options imply 39.1% move in share price post-earnings
15d ago
VXRT
Vaxart doses first subject in Phase 2 trial of bivalent norovirus candidate
The FlyVaxart doses first subject in Phase 2 trial of bivalent norovirus candidate
1M ago
VXRT
Vaxart names Phillip Lee as Chief Financial Officer
The FlyVaxart names Phillip Lee as Chief Financial Officer
3M ago
VXRT
Vaxart price target lowered to $1.50 from $6 at B. Riley
The FlyVaxart price target lowered to $1.50 from $6 at B. Riley
3M ago
VXRT
Vaxart announces collaborative funding for study on Novovirus vaccine candidate
The FlyVaxart announces collaborative funding for study on Novovirus vaccine candidate
4M ago
VXRT
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29
Press ReleasesVaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29
4M ago
VXRT
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
Press ReleasesVaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
4M ago
VXRT
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8
Press ReleasesVaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8
5M ago
VXRT
Vaxart to Present at World Vaccine Congress Europe 2022 on October 13
Press ReleasesVaxart to Present at World Vaccine Congress Europe 2022 on October 13
5M ago
VXRT
Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate
Press ReleasesVaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate
7M ago
VXRT
Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial
Press ReleasesVaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial
7M ago
VXRT
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
Press ReleasesVaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
7M ago
VXRT
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
Press ReleasesVaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
7M ago
VXRT
Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results
Press ReleasesVaxart Provides Business Update and Reports Second Quarter 2022 Financial Results
8M ago
VXRT
Vaxart Appoints W. Mark Watson to its Board of Directors
Press ReleasesVaxart Appoints W. Mark Watson to its Board of Directors
8M ago
VXRT
Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4
Press ReleasesVaxart Stockholders Approve Proxy Proposals 2, 3 and 4
8M ago
VXRT
Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive
Press ReleasesVaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive
8M ago
VXRT
Vaxart Announces Adjournment of Annual Meeting of Stockholders
Press ReleasesVaxart Announces Adjournment of Annual Meeting of Stockholders
10M ago
VXRT
Vaxart Has Great News if You’re Afraid of Covid-19 — And You’re a Hamster
Stock Analysis & IdeasVaxart Has Great News if You’re Afraid of Covid-19 — And You’re a Hamster
10M ago
VXRT
Is Vaxart Stock a Buy Right Now? This Is What You Need to Know
Stock Analysis & IdeasIs Vaxart Stock a Buy Right Now? This Is What You Need to Know
1y ago
VXRT
Vaxart’s Oral COVID-19 Vaccine Reflects Optimism; Shares Rise
Market NewsVaxart’s Oral COVID-19 Vaccine Reflects Optimism; Shares Rise
1y ago
VXRT
FDA Approves IND for Vaxart’s Oral Tablet; Shares Rise
Market NewsFDA Approves IND for Vaxart’s Oral Tablet; Shares Rise
2y ago
VXRT
Vaxart: Not Just a Covid-19 Play
Stock Analysis & IdeasVaxart: Not Just a Covid-19 Play
2y ago
VXRT
Vaxart Tanks 58% On Oral COVID-19 Vaccine Early Trial Data; Street Says Buy
Market NewsVaxart Tanks 58% On Oral COVID-19 Vaccine Early Trial Data; Street Says Buy
2y ago
VXRT
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.